Skip to main content

Table 5 Clinical and auxological data of seven PWS patients with diabetic microvascular complication

From: Prevalence and risk factors for type 2 diabetes mellitus with Prader–Willi syndrome: a single center experience

Patient no.

Sex

Genotype

Diagnosis age (yr)

Age at Cx onset (yr)

Duration until Cx onset (yr)

BMI, kg/m2 at Dx with DM

BMI, kg/m2 at Dx with Cx

A1C (%) at Dx with DM

A1C (%) at Dx with Cx

HOMA-IR

Duration of GHT

Duration of DM

Type of DMT

Type of Cx

PWS

DM

5

M

Del

10.1

15.0

23.5

8.5

47.55

38.25

7.3

14.0

7.7

NA

13.3

M- > M + S- > R- > N + M + S- > M + S- > M

DR

14

M

Del

1.8

13.8

15.0

1.2

22.53

25.28

9.6

7.2

8.5

3

2.0

M + B- > M

DR

75

M

Del

0.2

17.8

23.0

5.2

41.82

40.48

9.4

9.7

7.9

1.2

5.5

M + S- > M + S + B

DR

12

F

Del

4.8

14.7

19.0

4.3

30.48

29.59

6.9

11.3

10.2

7.5

5.0

M- > M + S- > M + S + B- > M + B + G

DR

44

F

Del

8.0

18.5

22.5

4.0

32.51

31.47

8.7

6.7

7.0

1.8

4.8

M

DN (Mi), DPN

55

F

Del

13.3

14.2

24.2

10.0

51.40

55.46

6.7

12.0

9.5

NA

11.4

M > M + S- > M + S + α- > M + S + α + G- > B + R + M

DN (P)

77

F

Del

27.0

27.0

27.0

0.0

40.20

40.20

12.1

12.1

7.6

NA

5.7

M + S + B

DN (Mi), DR, DPN

  1. Abbreviations: PWS Prader-Willi syndrome, DM Diabetes Mellitus, Del deletion, Cx microvascular complication, A1C hemoglobin A1C, HOMA-IR homeostasis model assessment, GHT Growth hormone treatment, DMT Treatment of diabetes mellitus, DN Diabetic nephropathy, DR Non-proliferative diabetic retinopathy, DPN Diabetic peripheral neuropathy, I insulin, PO Oral hypoglycemic drug